Year Founded
2005
Ownership
Private
Employees
~50
Therapeutic Areas
Dermatology
Stage
Phase 2
Modalities
Small molecule

TheraVida General Information

Lead product Anhydrix has completed Phase 2 study for primary focal hyperhidrosis with improved tolerability profile compared to existing therapies while maintaining efficacy

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Chapel Hill, North Carolina
United States

Drug Pipeline

Anhydrix
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to TheraVida's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

TheraVida Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view TheraVida's complete valuation and funding history, request access »

TheraVida Investors

Sanderling Ventures
Investor Type: Venture Capital
Holding: Minority